Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder [Phase 4]
A Phase 4 clinical trial update for brexpiprazole as adjunctive therapy in adults with major depressive disorder has completed with results …
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: Project Bridge: Peer Health Navigator Intervention [NA]
A completed clinical trial (Project Bridge) evaluating a Peer Health Navigator intervention for schizophrenia and depression; results posted…
-
FDA approval · 2024-02-01FDA Approved: BUPROPION HYDROCHLORIDE (XL) — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Bupropion Hydrochloride (XL) from Exelan Pharmaceuticals, authorizing continued marketing of the…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression [NA]
A completed clinical trial from Mayo Clinic investigated biomarkers associated with repetitive transcranial magnetic stimulation (rTMS) for …
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Sumor as Adjuvant Therapy in Treatment-resistant Major Depression [Phase 4]
Phase 4 clinical trial update for Sumor as adjuvant therapy in treatment-resistant major depressive disorder.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: Salicylic Augmentation in Depression [Phase 2]
Phase 2 trial investigating salicylic augmentation in depression was terminated; results posted in 2024.
-
FDA approval · 2024-01-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Epic Pharma, LLC, supporting the approval of a generic produc…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: The Effects of Sertraline on Depression in Parkinson's Disease [NA]
Completed clinical trial investigating the effects of sertraline on depression in Parkinson's disease; results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Mindfulness Based Cognitive Therapy for Recurrent Depression [NA]
A completed clinical trial evaluating mindfulness-based cognitive therapy for recurrent depression has posted results.
-
FDA approval · 2024-01-19FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Paroxetine by ANI Pharmaceuticals, Inc., indicating approval of a generic product under ANDA 215…
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: Pilot Decentralized Trial [Phase 2]
A Phase 2 pilot decentralized trial for Major Depressive Disorder has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder [Phase 4]
Phase 4 trial update assessing safety of Liposom With Citalopram in elderly patients with major depressive disorder.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Effect of Minocycline on Inflammation in Depressed Patients [Phase 2]
Phase 2 trial investigating the effect of minocycline on inflammation in patients with depression.
-
FDA approval · 2024-01-16FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for a combined olanzapine and fluoxetine product, submitted by Par Health USA, LLC (brand name Symby…
-
FDA approval · 2024-01-16FDA Approved: DOXEPIN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for the generic doxepin from Actavis Pharma, Inc., adding regulatory authorization for this prod…
-
CLINICAL_TRIALS trial_result · 2024-01-12Clinical Trial Update: Sleep to Prevent Evolving Affecting Disorders [NA]
Completed clinical trial investigating sleep-related interventions for insomnia and depression; results posted in 2024.
-
FDA approval · 2024-01-11FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for vilazodone hydrochloride submitted by Accord Healthcare Inc., allowing a generic version of the …
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: A Pilot Study of the Immediate Effects of DLPFC tDCS on Attention Bias in Depression [NA]
Pilot study assessing immediate effects of dorsolateral prefrontal cortex transcranial direct current stimulation on attention bias in depre…
-
FDA approval · 2024-01-09FDA Approved: FLUOXETINE — Supplemental Application (Vensun Pharmaceuticals, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride from Vensun Pharmaceuticals, Inc., granting approval of a generic fluox…
-
FDA approval · 2024-01-08FDA Approved: CITALOPRAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Citalopram by Amneal Pharmaceuticals LLC, indicating approval of a generic Citalopram product un…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Examining Validity and Reliability of the Shared Decision Making Process Survey in Adults With Depression
Completed clinical trial evaluating the validity and reliability of a Shared Decision Making Process Survey in adults with depression; resul…
-
CLINICAL_TRIALS withdrawal · 2024-01-05Clinical Trial Update: VA Aripiprazole vs Esketamine for Treatment Resistant Depression [Phase 4]
A Phase 4 trial comparing aripiprazole vs esketamine for treatment-resistant depression was withdrawn.
-
FDA approval · 2024-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for vilazodone hydrochloride (Alembic Pharmaceuticals Limited).
-
FDA approval · 2024-01-03FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for vilazodone hydrochloride, filed by Exelan Pharmaceuticals Inc. This indicates a supplemental app…
-
FDA approval · 2024-01-03FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited, confirming approval of the generic prod…